ASH 2013: Dr. Byrd on the New Data on Ibrutinib and Obinutuzumab in CLL In my final post from the last days of ASH 2013, my doctor, Dr. John Byrd out of Ohio State... Details
ASH 2013: Dr. John Byrd Discusses ONO-4059 and IPI-145 for the Treatment of CLL In the second of my three part interview from ASH 2013 with Dr. John Byrd from OSU, we discuss two... Details
ASH 2013: Giora Sharf and Jan Geissler Discuss Medication Adherence I am introducing a new subject, medication adherence, or the importance of taking our medications as prescribed. As C. Everett... Details
ASH 2013: Adherence, High Costs, and the Importance of Clear Communication In the second part of my interview from ASH 2013, I discuss adherence, cost and the importance of clear communication... Details
ASH 2013: Dr. Byrd Discusses Dinaciclib to Treat CLL (chronic lymphocytic leukemia) In the first of a three-part interview at ASH 2013 with Dr. John Byrd, my personal trial physician from Ohio State,... Details
